Bradley A. McGregor
Harvard University(US)Dana-Farber Cancer Institute(US)Dana-Farber/Harvard Cancer Center(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Cancer Genomics and Diagnostics, Prostate Cancer Treatment and Research
Most-Cited Works
- → Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy(2019)608 cited
- → Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma(2021)602 cited
- → Progressive immune dysfunction with advancing disease stage in renal cell carcinoma(2021)492 cited
- → Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology(2019)443 cited
- → Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma(2018)258 cited
- → Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial(2021)255 cited